Premium
ANTITUMOUR ACTIVITY OF CORDYCEPIN IN MICE
Author(s) -
Yoshikawa Noriko,
Nakamura Kazuki,
Yamaguchi Yu,
Kagota Satomi,
Shinozuka Kazumasa,
Kunitomo Masaru
Publication year - 2004
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/j.1440-1681.2004.04108.x
Subject(s) - cordycepin , cordyceps , inoculation , medicine , matrigel , pharmacology , adverse effect , toxicity , ratón , immunology , chemistry , angiogenesis , traditional medicine , biochemistry
SUMMARY 1. The antitumour effect of orally administered cordycepin, a component isolated from water extracts of Cordyceps sinensis , was examined in mice inoculated with B16 melanoma (B16‐BL6) cells. 2. B16‐BL6 (1 × 10 6 ) cells were inoculated subcutaneously into the right footpad of mice. At 2 weeks after the cell inoculation, the enlarged primary tumour lump was weighed. Cordycepin (0, 5 and 15 mg/kg per day) was administered orally to the mice for 2 weeks from the date of tumour inoculation. Cordycepin (15 mg/kg per day) significantly reduced by 36% the wet weight of the primary tumour lump compared to that of the untreated control mice, without any loss of bodyweight or systemic toxicity. 3. Cordycepin (15 mg/kg per day) administered orally for 2 weeks inhibited the tumour enlargement in the right thigh inoculated with B16‐BL6 cells premixed with extracellular matrix (Matrigel). 4. These results indicate that orally administered cordycepin inhibits melanoma cell growth in mice with no adverse effects.